Bio-Techne Q4 2024 Adj. EPS $0.49, Inline, Sales $306.098M Miss $306.491M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne (NASDAQ:TECH) reported Q4 2024 adjusted EPS of $0.49, meeting analyst expectations. However, the company missed its sales estimate by a small margin, reporting $306.098 million against the expected $306.491 million. This represents a 1.59% increase from the same period last year.
August 07, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bio-Techne's Q4 2024 earnings per share met analyst expectations at $0.49, but sales slightly missed estimates at $306.098 million, a 1.59% increase year-over-year.
The earnings per share meeting expectations is a neutral factor, while the slight miss in sales is a minor negative. The year-over-year sales increase is a positive, balancing the overall impact to neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100